Metabolomics Services Market by Area of Application (Biomarker Discovery, Personalized Medicine, Disease Diagnostics, Drug Discovery and Toxicological Testing), Type of Metabolomics Service(s) Offered (Targeted Metabolomics and Untargeted Metabolomics), Type of Metabolome Profiling Technique Used (LC-MS, GC-MS and NMR), Type of End User (Research / Academic Institutes, Pharma / Biotech Firms and CROs) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    April 2022

  • Pages
    266

  • View Count
    1988

Example Insights

Metabolomics-Services-Market-Context-thumb Metabolomics-Services-Market-List-of-Metabolomics-Service-Providers-thumb Metabolomics-Services-Market-Distribution-by-Type-of-Service-Provider-thumb
Metabolomics-Services-Market-Geographical-Distribution-thumb Metabolomics-Services-Market-Competitiveness-Analysis-thumb Metabolomics-Services-Market-Distribution-by-Type-of-Partnership-thumb
Metabolomics-Services-Market-Value-Creation-Framework-thumb Metabolomics-Services-Market-Likely-Growth-Scenarios-thumb Metabolomics-Services-Market-Distribution-by-Region-thumb

Overview

Since the initiation of the Human Metabolome Project in 2005, the metabolomics technique has gathered significant attention from the industry stakeholders. It is worth mentioning that about 40,000 small molecules constitute the human metabolome. Further, 30% of the known genetic disorders are associated with small-molecule metabolism. Therefore, metabolome profiling can assist in obtaining a better understanding of the disease. The approach has also demonstrated to be capable of identifying new biomarkers (for diagnosis and prognosis) and novel drug targets. In fact, 50% of the total drug candidates are reported to emanate from pre-existing metabolites. Integration of metabolomics with development projects holds the potential to significantly improve the efficiency and success rate of drug discovery, owing to its ability to differentiate promising candidates in the early stages. As a result, metabolomics has become an indispensable part of modern drug discovery and development process and disease diagnosis. Further, with the growing prominence of personalized medicine, there is an increased demand for rapid, highly sensitive and accurate quantification methods, such as metabolomics, to analyze clinical specimens. It is worth highlighting that various types of metabolite detection techniques, including targeted metabolomics and untargeted metabolomics, are being employed for diagnosis, severity determination and therapy development efforts against COVID-19. Specifically, studies have reported the potential implications of the serum metabolome in understanding the pathophysiology of the aforementioned disease.

Given the growing pipeline of biomarkers and drug discovery projects, the current demand for metabolite profiling is high. In this context, more than 18,000 drug candidates are being evaluated across different development stages, at present. Although some pharmaceutical companies have established in-house metabolomics research capabilities, significant capital investments and specialized requirements render this approach prohibitive for most stakeholders. Moreover, the associated metabolomics technologies, including chromatography and spectrometry, are complicated by multi-step analytical protocols and technically demanding expertise, which eventually leads to contamination of samples and lack of reproducibility in test results. This has created a demand for service providers having the required expertise in the global metabolomics market. In fact, since 2000, more than 70 players offering metabolomics services have been established. Amidst growing competition in the metabolomics services market, the implementation of cutting-edge tools and technologies, such as artificial intelligence, big data analytics, deep learning, machine learning and quantum computing, serves to differentiate the offerings of stakeholders. Hence, several service providers engaged in this upcoming market have actively begun expanding their respective service portfolios, either through undertaking strategic acquisitions or forming alliances with other specialty companies. Considering the ongoing advancements and active research efforts, the metabolomics services market size is anticipated to be quadruple in the foreseen future.

Scope of the Report

The “Metabolomics Services Market by Area of Application (Biomarker Discovery, Personalized Medicine, Disease Diagnostics, Drug Discovery and Toxicological Testing), Type of Metabolomics Service(s) Offered (Targeted Metabolomics and Untargeted Metabolomics), Type of Metabolome Profiling Techniques Used (LC-MS, GC-MS and NMR), Type of End User (Research / Academic Institutes, Pharma / Biotech Firms and CROs) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of the metabolomics services market. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing metabolomics services. Amongst other elements, the report features:

  • A detailed review of the overall landscape of companies offering metabolomics services to various organizations, including research / academic institutes, pharma / biotech firms and CROs, along with analysis based on various relevant parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. The chapter also provides details related to pre-profiling service(s) offered (experiment design and sample preparation), metabolomics service(s) offered (targeted metabolomics, untargeted metabolomics and unknown metabolite identification), additional services offered (lipidomics, metabolic flux analysis, proteomics, and xenobiotic metabolites analysis), type of metabolome profiling technique used (mass spectrometry, nuclear magnetic resonance, liquid chromatography, gas chromatography, inductively coupled plasma spectroscopy, capillary electrophoresis), type of approach used for data analysis (multivariate analysis, univariate analysis, preprocess and normalization, clustering analysis, enrichment analysis and classification and feature selection), type of biological sample analyzed (biological fluids, tissues, cells and stool), source of biological sample (animal, microbe, human and plant) and area of application (biomarker discovery, disease diagnostics, drug discovery, toxicological testing and personalized medicine). 
  • An in-depth analysis, highlighting the contemporary market trends, using eight schematic representations, including [A] waffle chart representations (based on regional distribution of various industry and non-industry players), [B] world map representations (based on the country-wise distribution of various industry and non-industry players), [C] a horizontally stacked bar chart representation (based on company / organization size and type of service provider), [D] a mekko chart representation (based on area of application and company / organization size), [E] a vertically stacked bar chart representation (based on type of metabolome profiling technique used and type of biological sample analyzed), [F] a tree map representation (based on type of metabolome profiling technique and area of application), [G] a 4D bubble analysis comparing the key players engaged in this domain, based on several relevant parameters (such as year of establishment, number of metabolomics services offered, company / organization size and region), [H] a grid representation (based on company / organization size, region, type of metabolomics services offered, type of metabolome profiling technique used and area of application).
  • An in-depth company competitiveness analysis of metabolomics service providers, segmented into four categories, namely large and very large (>500 employees), mid-sized (51-500 employees), small (11-50 employees) and very small companies (<10 employees). Within the peer group, companies were ranked based on various relevant parameters, such as supplier power (based on the experience) and portfolio strength (based on parameters, such as number of pre-profiling profiling services offered, number of additional services offered, type of metabolome profiling technique used, type of approach used for data analysis, type of biological sample analysed, source of biological sample analysed and area of application), as well as partnership activity (in terms of number of partnerships and type of agreement).
  • Elaborate profiles of various prominent players that are currently engaged in offering metabolomics services. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its recent developments and an informed future outlook.
  • An analysis of the partnerships that have been inked between several stakeholders engaged in providing metabolomic services, during the period 2014-2022, covering research agreements, R&D agreements, commercialization agreements, metabolomics data sharing agreements, acquisitions, service alliances, product development agreements and other agreements.
  • An insightful framework depicting the implementation of several advanced tools and technologies, such as artificial intelligence, big data analytics, block chain, cloud computing, deep learning, machine learning and quantum computing, at different stages of a metabolomics study, which can assist service providers in addressing existing unmet needs. Further, it provides a detailed analysis on ease of implementation and associated risk in integrating above-mentioned technologies, based on the trends highlighted in published literature and patents.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for metabolomics services market in the next 13 years. Additionally, it features market size projections for the metabolomics services market, wherein both the current and upcoming opportunity is segmented across [A] area of application (biomarker discovery, personalized medicine, disease diagnostics, drug discovery and toxicological testing), [B] type of metabolomics service (targeted metabolomics and untargeted metabolomics), [C] type metabolome profiling technique (LC-MS, GC-MS and NMR), [D] type of end user (academic / research institutes,  pharma / biotech firms, and CROs) and [E] key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Oliver Schimts (Head of Metabolome Data Science, BASF Metabolome Solutions)
  • Manoj Kumar (Indian Representative – Eroth Technologies, biocrates life sciences)
  • Bernhard Drotleff (Scientific Officer, European Molecular Biology Laboratory)
  • Morten Danielsen (Chief Executive Officer, MS-Omics)
  • Gilbert Skorski (Chairman and Chief Executive Officer, Phylogene)

Key Questions Answered

  • Who are the leading players engaged in providing metabolomics services?
  • Which metabolomics services are most commonly offered by service providers engaged in this market?
  • What is the relative competitiveness of metabolomics service providers?
  • What types of partnership models are commonly being adopted by stakeholders in this industry? 
  • What is the likely performance enhancement value upon integrating novel tools / technologies in metabolomics studies?
  • Which key market trends and driving factors are likely to impact the growth of the metabolomics services market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured during our research. The chapter offers a high-level view on the likely evolution of the metabolomics services market in the short to mid-term and long term.

Chapter 3 provides a general introduction to metabolomics, featuring information on various steps involved in the overall process. Further, it provides a detailed discussion on different approaches for metabolomics. In addition, the chapter includes details related to various applications and challenges associated with metabolomic studies. The chapter concludes with a discussion on key growth drivers, as well as upcoming trends in this field.

Chapter 4 includes detailed assessment of the overall landscape of the players offering metabolomics services to various organizations, including pharma / biotech firms, CROs and research / academic institutes, along with information on their year of establishment, company size (in terms of employee count) and location of headquarters (North America, Europe, Asia, Middle East and North Africa and Rest of The World). The chapter also provides details related to pre-profiling service(s) offered (experiment design and sample preparation), metabolomics service(s) offered (targeted metabolomics, untargeted metabolomics and unknown metabolite identification), additional services offered (lipidomics, metabolic flux analysis, proteomics, and xenobiotic metabolites analysis), type of metabolome profiling technique used (mass spectrometry, nuclear magnetic resonance, liquid chromatography, gas chromatography, inductively coupled plasma spectroscopy, capillary electrophoresis), type of approach used for data analysis (multivariate analysis, univariate analysis, preprocess and normalization, clustering analysis, enrichment analysis and classification and feature selection), type of biological sample analyzed (biological fluids, tissues, cells and stool), source of biological sample (animal, microbe, human and plant), and area of application (biomarker discovery, disease diagnostics, drug discovery, toxicological testing and personalized medicine). 

Chapter 5 features an analysis, highlighting the contemporary market trends through eight schematic representations, including waffle chart representations based on regional distribution of various industry and non-industry players, world map representations based on the country-wise distribution of various industry and non-industry players, a horizontally stacked bar chart representation based on company / organization size and type of service provider,  a mekko chart representation based on area of application and company / organization size, a vertically stacked bar chart representation based on type of metabolome profiling technique used and type of biological sample analyzed, a tree map representation based on type of metabolome profiling technique and area of application,  a 4D bubble analysis comparing the key players engaged in this domain, based on several relevant parameters (such as year of establishment, number of metabolomics services offered, company / organization size and region), and a grid representation based on company / organization size, region, type of metabolomics services offered, type of metabolome profiling technique used and area of application.

Chapter 6 provides an in-depth competitiveness analysis of metabolomics service providers, segmented into four categories, namely large and very large (>500 employees), mid-sized (51-500 employees), small (11-50 employees) and very small companies (<10 employees). Within the peer group, companies were ranked based on various relevant parameters, such as supplier power (based on the experience), their respective capabilities (number of pre-profiling profiling services offered, number of additional services offered, type of metabolome profiling technique used, type of approach used for data analysis, type of biological sample analysed, source of biological sample analysed and area of application) and partnership activity (in terms of number of partnerships and type of agreement).

Chapter 7 includes detailed profiles of prominent players (shortlisted based on company competitiveness analysis) engaged in providing metabolomics services. Each profile features a brief overview of the company including information on several relevant parameters such as (year of establishment, number of employees, location of headquarters and key executives). Further, the chapter also features details on recent developments and an informed future outlook.

Chapter 8 features an insightful analysis of the various partnerships and collaborations that have been inked amongst players in this market, during the period 2014-2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership (research agreements, R&D agreements, commercialization agreements, metabolomics data sharing agreements, acquisitions, service alliances, product development agreements, and other related agreements), type of partner (academic / research institutes, pharma / biotech firms, contract research organizations), type of metabolomics service(s) offered (targeted metabolomics and untargeted metabolomics), type of metabolome profiling technique used (LC-MS, GC-MS, NMR), area of application (biomarker discovery, disease diagnostics, drug discovery) and regional distribution of the collaborations.

Chapter 9 features an insightful framework depicting the implementation of several advanced tools and technologies, such as artificial intelligence, big data analytics, block chain, cloud computing, deep learning, machine learning, and quantum computing, at different stages of a metabolomics study, which can assist service providers to address unmet needs associated with such services. Further, it provides a detailed analysis on ease of implementation and associated risk in integrating above-mentioned technologies, based on the trends highlighted in published literature and patents.

Chapter 10 presents an insightful market forecast analysis, highlighting the future potential of metabolomics services market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented across important market segments, namely [A] area of application (biomarker discovery, personalized medicine, disease diagnostics, drug discovery and toxicological testing), [B] type of metabolomics services (targeted metabolomics and untargeted metabolomics), [C] type metabolome profiling techniques (LC-MS, GC-MS and NMR), [D] type of end user (academic / research institutes,  pharma / biotech firms, and CROs) and [E] key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world).

Chapter 11 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 12 provides the transcripts of interviews conducted with several key stakeholders of this market. In this chapter, we have presented the details of our conversation with Olivier Schmitz (Head of Metabolome Data Science, BASF Metabolome Solutions), Manoj Kumar (Indian Partner - Eroth Technologies, biocrates life sciences), Bernhard Drotleff (Scientific Officer, European Molecular Biology Laboratory), Morten Danielsen (Chief Executive Officer, MS-Omics) and Gilbert Skorski (Chairman and Chief Executive Officer, Phylogene).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Metabolomics
3.3. Steps Involved in a Metabolomics Study
3.3.1. Experimental Design
3.3.2. Sample Preparation
3.3.3. Data Acquisition
3.3.4. Data Processing
3.3.5. Statistical Analysis

3.4. Approaches Used for Metabolomics Analysis
3.4.1. Targeted Metabolomics
3.4.2. Untargeted Metabolomics
3.4.3. Unknown Metabolite Identification

3.5. Applications of Metabolomics
3.6. Challenges Related to Metabolomics
3.7. Need for Outsourcing Metabolomics Operations
3.8. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Metabolomics Service Providers: Overall Market Landscape
4.3. Metabolomics Service Providers: Industry Players
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Type of Pre-Profiling Service(s) Offered
4.3.5. Analysis by Type of Metabolomic Service(s) Offered
4.3.6. Analysis by Type of Additional Service(s) Offered
4.3.7. Analysis by Type of Metabolome Profiling Technique Used
4.3.8. Analysis by Type of Approach Used for Data Analysis
4.3.9. Analysis by Type of Biological Sample Analyzed
4.3.10. Analysis by Source of Biological Sample
4.3.11. Analysis by Area of Application

4.4. Metabolomics Service Providers: Non-Industry Players
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Organization Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Type of Pre-Profiling Service(s) Offered
4.4.5. Analysis by Type of Metabolomic Service(s) Offered
4.4.6. Analysis by Type of Additional Service(s) Offered
4.4.7. Analysis by Type of Metabolome Profiling Technique Used
4.4.8. Analysis by Type of Approach Used for Data Analysis
4.4.9. Analysis by Type of Biological Sample Analyzed
4.4.10. Analysis by Source of Biological Sample
4.4.11. Analysis by Area of Application

5. KEY INSIGHTS
5.1. Chapter Overview
5.1.1 Analysis by Location of Headquarters and Type of Service Provider (Waffle Chart and World Map Representation)
5.1.2 Analysis by Company / Organization Size and Type of Service Provider (Horizontally Stacked Bar Chart)
5.1.3 Analysis by Area of Application and Company / Organization Size (Mekko Chart)
5.1.4 Analysis by Type of Metabolome Profiling Technique Used and Type of Biological Sample Analyzed (Vertically Stacked Bar Chart)
5.1.5 Analysis by Type of Metabolome Profiling Technique Used and Area of Application (Treemap Representation)
5.1.6 Analysis by Year of Establishment, Company / Organization Size, Number of Metabolomics Service(s) Offered and Region (4D Bubble Chart)
5.1.7 Analysis by Company / Organization Size, Region, Type of Metabolomics Service(s) Offered, Type of Metabolome Profiling Technique Used and Area of Application (Grid Representation)

6. COMPANY COMPETITIVENESS 
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.3.1. Company Competitiveness Analysis: Benchmarking of Service Strength
6.3.2. Company Competitiveness Analysis: Benchmarking of Partnership activity
6.3.3. Company Competitiveness Analysis: Very Small Companies
6.3.4. Company Competitiveness Analysis: Small Companies
6.3.5. Company Competitiveness Analysis: Mid-Sized Companies
6.3.6. Company Competitiveness Analysis: Large and Very Large Companies

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. biocrates life sciences
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook

7.3. Creative Proteomics
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook

7.4. DNA Xperts
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook

7.5. Eremid Research Services 
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook

7.6. Human Metabolome Technologies (HMT)
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook

7.7. Metabo Profile
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook

7.8. Metabolon
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook

7.9. MS-Omics
7.9.1. Company Overview
7.9.2. Recent Developments and Future Outlook

7.10. Novelgene Technologies
7.10.1. Company Overview
7.10.2. Recent Developments and Future Outlook

7.11. Synbio Technologies
7.11.1. Company Overview
7.11.2. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Metabolomics Service Providers: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.2.1 Analysis by Year and Type of Partnership
8.3.2.2 Analysis by Type of Partnership and Company Size

8.3.3. Analysis by Type of Partner
8.3.4. Analysis by Type of Metabolomics Service(s) Offered
8.3.5. Analysis by Type of Metabolome Profiling Technique Used 
8.3.6. Analysis by Area of Application
8.3.7. Most Active Players: Analysis by Number of Partnerships

8.3.8. Regional Analysis
8.3.8.1 Local and International Deals 
8.3.8.2 Intercontinental and Intracontinental Deals
8.3.8.3 Analysis by Location of Headquarters of Partner
8.3.8.4 Analysis by Type of Partnership and Location of Headquarters of Partner

9. VALUE CREATION FRAMEWORK: A STRATEGIC GUIDE TO ADDRESS UNMET NEED IN METABOLOMICS
9.1. Chapter Overview
9.2. Unmet Need in Metabolomics
9.3. Sensitivity and Selectivity: Key Tools and Technologies
9.3.1. Key Assumptions and Methodology
9.3.2. Dynamic Nuclear Polarization (DNP)
9.3.3. Technology B
9.3.4. Technology C
9.3.5 Results and Discussion

9.4. Data Processing: Key Tools and Technologies
9.4.1. Key Assumptions and Methodology
9.4.2. Artificial Intelligence
9.4.3. Technology E
9.4.4. Technology F
9.4.5. Technology I
9.4.6. Technology J
9.4.7. Technology K
9.4.8. Quantum Computing
9.4.9. Trends in Research Activity
9.4.10. Extent of Innovation versus Associated Risks
9.4.11. Results and Discussion
9.4.12. Results and Discussion

10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Metabolomics Services Market, 2022-2035

10.4. Metabolomics Services Market: Analysis by Area of Application, 2022 and 2035
10.4.1. Metabolomics Services Market for Biomarker Discovery, 2022- 2035
10.4.2. Metabolomics Services Market for Personalized Medicine, 2022-2035
10.4.3. Metabolomics Services Market for Drug Discovery, 2022-2035
10.4.4. Metabolomics Services Market for Disease Diagnostics, 2022- 2035
10.4.5. Metabolomics Services Market for Toxicological Testing, 2022-2035

10.5. Metabolomics Services Market: Analysis by Type of Metabolomics Service Offered, 2022 and 2035
10.5.1. Metabolomics Services Market for Targeted Metabolomics, 2022-2035
10.5.2. Metabolomics Services Market for Untargeted Metabolomics, 2022-2035

10.6. Metabolomics Services Market: Analysis by Type of Metabolome Profiling Technique Used, 2022 and 2035
10.6.1. Metabolomics Services Market for LC-MS Technique, 2022-2035
10.6.2. Metabolomics Services Market for GC-MS Technique, 2022-2035
10.6.3. Metabolomics Services Market for NMR Technique, 2022-2035

10.7. Metabolomics Services Market: Analysis by Type of End User, 2022 and 2035
10.7.1. Metabolomics Services Market for Academic / Research Institutes, 2022-2035
10.7.2. Metabolomics Services Market for Pharma / Biotech Companies, 2022-2035
10.7.3. Metabolomics Services Market for Contract Research Organizations (CROs), 2022-2035

10.8. Metabolomics Services Market: Analysis by Key Geographical Regions, 2022 and 2035
10.8.1. Metabolomics Services Market in North America, 2022-2035
10.8.2. Metabolomics Services Market in Europe, 2022-2035
10.8.3. Metabolomics Services Market in Asia, 2022-2035
10.8.4. Metabolomics Services Market in Latin America, 2022-2035
10.8.5. Metabolomics Services Market in Middle East and North Africa (MENA), 2022-2035
10.8.6. Metabolomics Services Market in Rest of the World, 2022-2035

10.9. Concluding Remarks

11. CONCLUSION

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. BASF Metabolome Solutions
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Olivier Schmitz, Head of Metabolome Data Science

12.3. biocrates life sciences
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Manoj, Indian Partner (Eroth Technologies)

12.4 European Molecular Biology Laboratory (EMBL)
12.4.1. Company Snapshot
12.4.1. Interview Transcript: Bernhard Drotleff, Scientific Officer

12.5. MS-Omics
12.5.1. Company Snapshot
12.5.2. Interview Transcript: Morten Danielsen, Chief Executive Officer

12.6. Phylogene
12.6.1. Company Snapshot
12.6.2. Interview Transcript: Gilbert Skorski, Chairman and Chief Executive Officer

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape (I/II)
Figure 2.2 Executive Summary: Overall Market Landscape (II/II)
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Market Forecast
Figure 3.1 Metabolomics Process
Figure 3.2 Applications of Metabolomics
Figure 3.3 Challenges Related to Metabolomics
Figure 4.1 Metabolomics Service Providers: Distribution by Type of Service Provider
Figure 4.2 Metabolomics Service Providers (Industry Players): Distribution by Year of Establishment
Figure 4.3 Metabolomics Service Providers (Industry Players): Distribution by Company Size
Figure 4.4 Metabolomics Service Providers (Industry Players): Distribution by Location of Headquarters
Figure 4.5 Metabolomics Service Providers (Industry Players): Distribution by Company Size and Location of Headquarters
Figure 4.6 Metabolomics Service Providers (Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Figure 4.7 Metabolomics Service Providers (Industry Players): Distribution by Type of Metabolomics Service(s) Offered
Figure 4.8 Metabolomics Service Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Figure 4.9 Metabolomics Service Providers (Industry Players): Distribution by Type Detection Technique Used
Figure 4.10 Metabolomics Service Providers (Industry Players): Distribution by Type of Separation Technique
Figure 4.11 Metabolomics Service Providers (Industry Players): Distribution by Type of Approach Used for Data Analysis
Figure 4.12 Metabolomics Service Providers (Industry Players): Distribution by Type of Biological Sample Analyzed
Figure 4.13 Metabolomics Service Providers (Industry Players): Distribution by Source of Biological Sample
Figure 4.14 Metabolomics Service Providers (Industry Players): Distribution by Area of Application
Figure 4.15 Metabolomics Service Providers (Non-Industry Players): Distribution by Year of Establishment
Figure 4.16 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size
Figure 4.17 Metabolomics Service Providers (Non-Industry Players): Distribution by Location of Headquarters
Figure 4.18 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size and Location of Headquarters
Figure 4.19 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Figure 4.20 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Metabolomics Service(s) Offered
Figure 4.21 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Additional Service(s) Offered
Figure 4.22 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Detection Technique Used
Figure 4.23 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Separation Technique Used
Figure 4.24 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Approach Used for Data Analysis
Figure 4.25 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Biological Sample Analyzed
Figure 4.26 Metabolomics Service Providers (Non-Industry Players): Distribution by Source of Biological Sample
Figure 4.27 Metabolomics Service Providers (Non-Industry Players): Distribution by Area of Application
Figure 5.1 Key Insights: Distribution by Location of Headquarters (Region-wise) and Type of Service Provider
Figure 5.2 Key Insights: Distribution of Industry Players by Location of Headquarters (Country-wise)
Figure 5.3 Key Insights: Distribution of Non-Industry Players by Location of Headquarters (Country-wise)
Figure 5.4 Key Insights: Distribution by Company / Organization Size and Type of Service Provider
Figure 5.5 Key Insights: Distribution by Area of Application and Company / Organization Size
Figure 5.6 Key Insights: Distribution by Type of Metabolome Profiling Technique Used and Type of Biological Sample Analyzed
Figure 5.7 Key Insights: Distribution by Type of Metabolome Profiling Technique and Area of Application
Figure 5.8 Key Insights: Distribution by Year of Establishment, Company / Organization Size, Number of Metabolomics Service(s) Offered and Region
Figure 5.9 Key Insights: Distribution by Company / Organization Size, Region, Type of Metabolomic Service(s) Offered, Type of Metabolome Profiling Technique Used and Area of Application
Figure 6.1 Company Competitiveness Analysis: Benchmarking of Service Strength
Figure 6.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Figure 6.3 Company Competitiveness Analysis: Very Small Companies
Figure 6.4 Company Competitiveness Analysis: Small Companies
Figure 6.5 Company Competitiveness Analysis: Mid-sized Companies
Figure 6.6 Company Competitiveness Analysis: Large and Very Large Companies
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Year-wise Distribution by Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Figure 8.8 Partnerships and Collaborations: Distribution by Type of Metabolomic Service(s) Offered
Figure 8.9 Partnerships and Collaborations: Distribution by Area of Application
Figure 8.10 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Application
Figure 8.11 Most Active Players: Distribution by Number of Partnerships
Figure 8.12 Partnerships and Collaborations: Local and International Agreements
Figure 8.13 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 9.1 Value Creation Framework: Likely Sensitivity Enhancement by Implementation of Key Tools and Technologies
Figure 9.2 Value Creation Framework: Trends in Research Activity related to Integration of Key Tools and Technologies with Metabolomics
Figure 9.3 Value Creation Framework: Trends in Intellectual Property related to Integration of Key Tools and Technologies with Metabolomics
Figure 9.4 Value Creation Framework: Extent of Innovation versus Associated Risk Matrix
Figure 9.5 Value Creation Framework: Comparison of Key Tools / Technologies
Figure 10.1 Global Metabolomics Services Market, 2022-2035 (USD Million)
Figure 10.2 Metabolomics Services Market: Distribution by Area of Application, 2022 and 2035
Figure 10.3 Metabolomics Services Market for Biomarker Discovery, 2022-2035 (USD Million)
Figure 10.4 Metabolomics Services Market for Personalized Medicine, 2022-2035 (USD Million)
Figure 10.5 Metabolomics Services Market for Disease Diagnostics, 2022-2035 (USD Million)
Figure 10.6 Metabolomics Services Market for Drug Discovery, 2022-2035 (USD Million)
Figure 10.7 Metabolomics Services Market for Toxicological Testing, 2022-2035 (USD Million)
Figure 10.8 Metabolomics Services Market: Distribution by Type of Metabolomics Service(s) Offered 2022 and 2035
Figure 10.9 Metabolomics Services Market for Targeted Metabolomics, 2022-2035 (USD Million)
Figure 10.10 Metabolomics Services Market for Untargeted Metabolomics, 2022-2035 (USD Million)
Figure 10.11 Metabolomics Services Market: Distribution by Type of Metabolome Profiling Technique Used, 2022 and 2035
Figure 10.12 Metabolomics Services Market for LC-MS Technique, 2022-2035 (USD Million)
Figure 10.13 Metabolomics Services Market for GC-MS Technique, 2022-2035 (USD Million)
Figure 10.14 Metabolomics Services Market for NMR Technique, 2022-2035 (USD Million)
Figure 10.15 Metabolomics Services Market: Distribution by Type of End User, 2022 and 2035
Figure 10.16 Metabolomics Services Market for Academic / Research Institutes, 2022-2035 (USD Million)
Figure 10.17 Metabolomics Services Market for Pharma / Biotech Companies, 2022-2035 (USD Million)
Figure 10.18 Metabolomics Services Market for Contract Research Organizations (CROs), 2022-2035 (USD Million)
Figure 10.19 Metabolomics Services Market: Distribution by Key Geographical Regions, 2022 and 2035 (USD Million)
Figure 10.20 Metabolomics Services Market in North America, 2022-2035 (USD Million)
Figure 10.21 Metabolomics Services Market in Europe, 2022-2035 (USD Million)
Figure 10.22 Metabolomics Services Market in Asia, 2022-2035 (USD Million)
Figure 10.23 Metabolomics Services Market in Latin America, 2022-2035 (USD Million)
Figure 10.24 Metabolomics Services Market in Middle East and North Africa (MENA), 2022-2035 (USD Million)
Figure 10.25 Metabolomics Services Market in Rest of the World, 2022-2035 (USD Million)
Figure 10.26 Metabolomics Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Million)
Figure 11.1 Concluding Remarks: Current Market Landscape
Figure 11.2 Concluding Remarks: Partnerships and Collaborations
Figure 11.3 Concluding Remarks: Market Forecast (I/II)
Figure 11.4 Concluding Remarks: Market Forecast (II/II)

List Of Tables

Table 3.1 Comparison between Mass Spectrometry and Nuclear Magnetic Resonance
Table 4.1 Metabolomics Service Providers: List of Players
Table 4.2 Metabolomics Service Providers: List of Industry Players
Table 4.3 Metabolomics Service Providers (Industry Players): Information on Type of Pre-Profiling Service(s) Offered
Table 4.4 Metabolomics Service Providers (Industry Players): Information on Type of Metabolomic Service(s) Offered
Table 4.5 Metabolomics Service Providers (Industry Players): Information on Type of Additional Service(s) Offered
Table 4.6 Metabolomics Service Providers (Industry Players): Information on Type of Metabolome Profiling Technique Used
Table 4.7 Metabolomics Service Providers (Industry Players): Information on Type of Approach Used for Data Analysis
Table 4.8 Metabolomics Service Providers (Industry Players): Information on Type of Biological Sample Analyzed
Table 4.9 Metabolomics Service Providers (Industry Players): Information on Source of Biological Sample
Table 4.10 Metabolomics Service Providers (Industry Players): Information on Area of Application
Table 4.11 Metabolomics Service Providers: List of Non-Industry Players
Table 4.12 Metabolomics Service Providers (Non-Industry Players): Information on Type of Pre-Profiling Service(s) Offered
Table 4.13 Metabolomics Service Providers (Non-Industry Players): Information on Type of Metabolomic Service(s) Offered
Table 4.14 Metabolomics Service Providers (Non-Industry Players): Information on Type of Additional Service(s) Offered
Table 4.15 Metabolomics Service Providers (Non-Industry Players): Information on Type of Metabolome Profiling Technique Used
Table 4.16 Metabolomics Service Providers (Non-Industry Players): Information on Type of Approach Used for Data Analysis
Table 4.17 Metabolomics Service Providers (Non-Industry Players): Information on Type of Biological Sample Analyzed
Table 4.18 Metabolomics Service Providers (Non-Industry Players): Information on Source of Biological Sample
Table 4.19 Metabolomics Service Providers (Non-Industry Players): Information on Area of Application
Table 6.1 Company Competitiveness Analysis: Benchmarking of Service Strength
Table 6.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 6.3 Company Competitiveness Analysis: List of Very Small Players
Table 6.4 Company Competitiveness Analysis: List of Small Players
Table 6.5 Company Competitiveness Analysis: List of Mid-sized Players
Table 6.6 Company Competitiveness Analysis: List of Large and Very Large Players
Table 7.1 Metabolomics Service Providers: List of Companies Profiled
Table 7.2 biocrates life sciences: Company Overview
Table 7.3 biocrates life sciences: Recent Developments and Future Outlook
Table 7.4 Creative Proteomics: Company Overview
Table 7.5 DNA Xperts: Company Overview
Table 7.6 Eremid Research Services: Company Overview
Table 7.7 Eremid Research Services: Recent Developments and Future Outlook
Table 7.8 Human Metabolome Technologies (HMT): Company Overview
Table 7.9 Human Metabolome Technologies (HMT): Recent Developments and Future Outlook
Table 7.10 Metabo Profile: Company Overview
Table 7.11 Metabo Profile: Recent Developments and Future Outlook
Table 7.12 Metabolon: Company Overview
Table 7.13 Metabolon: Recent Developments and Future Outlook
Table 7.14 MS-Omics: Company Overview
Table 7.15 MS-Omics: Recent Developments and Future Outlook
Table 7.16 Novelgene Technologies: Company Overview
Table 7.17 Synbio Technologies: Company Overview
Table 7.18 Synbio Technologies: Recent Developments and Future Outlook
Table 8.1 Metabolomics Services: List of Collaborations, 2015-2021
Table 8.2 Metabolomics Services: Partnerships and Collaborations, Information on Type of Agreement (Region-wise and Geography-wise)
Table 8.3 Metabolomics Services: Partnerships and Collaborations, Information on Metabolomics Service(s) Offered and Area of Application
Table 12.1 BASF Metabolome Solutions: Company Snapshot
Table 12.2 European Molecular Biology Laboratory (EMBL): Company Snapshot
Table 12.3 Phylogene: Company Snapshot
Table 13.1 Metabolomic Service Providers: Distribution by Type of Service Provider
Table 13.2 Metabolomics Service Providers (Industry Players): Distribution by Year of Establishment
Table 13.3 Metabolomics Service Providers (Industry Players): Distribution by Company Size
Table 13.4 Metabolomics Service Providers (Industry Players): Distribution by Location of Headquarters
Table 13.5 Metabolomics Service Providers (Industry Players): Distribution by Company
Table 13.6 Metabolomics Service Providers (Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Table 13.7 Metabolomics Service Providers (Industry Players): Distribution by Type of Metabolomic Service(s) Offered
Table 13.8 Metabolomics Service Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Table 13.9 Metabolomics Service Providers (Industry Players): Distribution by Type Detection Technique Used
Table 13.10 Metabolomics Service Providers (Industry Players): Distribution by Type Separation Technique Used
Table 13.11 Metabolomics Service Providers (Industry Players): Distribution by Type of Approach used for Data Analysis
Table 13.12 Metabolomics Service Providers (Industry Players): Distribution by Type of Biological Sample Analyzed
Table 13.13 Metabolomics Service Providers (Industry Players): Distribution by Source of Biological Sample
Table 13.14 Metabolomics Service Providers (Industry Players): Distribution by Area of Application
Table 13.15 Metabolomics Service Providers (Non-Industry Players): Distribution by Year of Establishment
Table 13.16 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size
Table 13.17 Metabolomics Service Providers (Non-Industry Players): Distribution by Location of Headquarters
Table 13.18 Metabolomics Service Providers (Non-Industry Players): Distribution by Organization Size and Location of Headquarters
Table 13.19 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Pre-Profiling Service(s) Offered
Table 13.20 Metabolomics Service Providers (Non-Industry Players): Distribution by Metabolomics Service(s) Offered
Table 13.21 Metabolomics Service Providers (Non-Industry Players): Distribution by Additional Service(s) Offered
Table 13.22 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Detection Technique Used
Table 13.23 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Detection Technique Used
Table 13.24 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Approach used for Data Analysis
Table 13.25 Metabolomics Service Providers (Non-Industry Players): Distribution by Type of Biological Sample Analyzed
Table 13.26 Metabolomics Service Providers (Non-Industry Players): Distribution by Source of Biological Sample
Table 13.27 Metabolomics Service Providers (Non-Industry Players): Distribution by Area of Application
Table 13.28 Key Insights: Distribution by Location of Headquarters (Region-wise) and Type of Service Provider
Table 13.29 Key Insights: Distribution of Industry Players by Location of Headquarters (Country-wise)
Table 13.30 Key Insights: Distribution of Non-Industry Players by Location of Headquarters (Country-wise)
Table 13.31 Key Insights: Distribution by Company / Organization Size and Type of Service Provider
Table 13.32 Key Insights: Distribution by Area of Application and Company / Organization Size
Table 13.33 Key Insights: Distribution by Type of Metabolome Profiling Technique Used and Type of Biological Sample Analyzed
Table 13.34 Key Insights: Distribution by Type of Metabolome Profiling Technique and Area of Application
Table 13.35 Company Competitiveness Analysis: Benchmarking of Services Strength
Table 13.36 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 13.37 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2022
Table 13.38 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.39 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 13.40 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 13.41 Partnerships and Collaborations: Distribution by Type of Partner
Table 13.42 Partnerships and Collaborations: Distribution by Type of Metabolomics Service(s) Offered
Table 13.43 Partnerships and Collaborations: Distribution by Type of Metabolome Profiling Technique Used
Table 13.44 Partnerships and Collaborations: Distribution by Area of Application
Table 13.45 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Application
Table 13.46 Most Active Players: Distribution by Number of Partnerships
Table 13.47 Partnerships and Collaborations: Local and International Agreements
Table 13.48 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 13.49 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner (Country-wise)
Table 13.50 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Table 13.51 Value Creation Framework: Distribution by Relative Sensitivity and Key Tools and Technologies
Table 13.52 Trends in Intellectual Property related to Integration of Key Tools and Technologies with Metabolomics
Table 13.53 Value Creation Framework: Extent of Innovation versus Associated Risk Analysis
Table 13.54 Value Creation Framework: Implementation of Key Tools / Technologies
Table 13.55 Metabolomics Services Market, 2022-2035 (USD Million)
Table 13.56 Metabolomics Services Market: Distribution by Area of Application, 2022 and 2035
Table 13.57 Metabolomics Services Market for Biomarker Discovery, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.58 Metabolomics Services Market for Personalized Medicine, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.59 Metabolomics Services Market for Disease Diagnostics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.60 Metabolomics Services Market for Drug Discovery, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.61 Metabolomics Services Market for Toxicological Testing, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.62 Metabolomics Services Market: Distribution by Type of Metabolomics Service(s) Offered, 2022 and 2035
Table 13.63 Metabolomics Services Market for Targeted Metabolomics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.64 Metabolomics Services Market for Untargeted Metabolomics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.65 Metabolomics Services Market: Distribution by Type of Metabolome Profiling Technique Used, 2022 and 2035
Table 13.66 Metabolomics Services Market for LC-MS Technique, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.67 Metabolomics Services Market for GC-MS Technique, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.68 Metabolomics Services Market for NMR Technique, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.69 Metabolomics Services Market: Distribution by Type of End User, 2022 and 2035
Table 13.70 Metabolomics Services Market for Academic / Research Institutes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.71 Metabolomics Services Market for Pharma / Biotech Companies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.72 Metabolomics Services Market for Contract Research Organizations (CROs), Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.73 Metabolomics Services Market: Distribution by Key Geographical Regions, 2022 and 2035 (USD Million)
Table 13.74 Metabolomics Services Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.75 Metabolomics Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.76 Metabolomics Services Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.77 Metabolomics Services Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.78 Metabolomics Services Market in Middle East and North Africa (MENA), Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.79 Metabolomics Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 13.80 Metabolomics Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 1st BASE 
  2. Abramson Cancer Center, Penn Medicine
  3. Absorption Systems (acquired by Pharmaron)
  4. Afekta Technologies
  5. Agilent Technologies
  6. Albert Einstein College of Medicine
  7. Analytica Laboratories
  8. AnGes
  9. Anti-Doping Laboratory Qatar
  10. ARC-BIO, Colorado State University
  11. Arome Science
  12. AstraZeneca
  13. Augusta University
  14. Australian Institute for Bioengineering and Nanotechnology (AIBN)
  15. Axon Scientific
  16. AXYS Analytical Services
  17. AYOXXA
  18. Barc Lab
  19. BASF Metabolome Solutions
  20. Bayer
  21. Baylor College of Medicine
  22. BERG
  23. Beth Israel Deaconess Medical Center
  24. Beth Israel Deaconess Medical Center (BIDMC)
  25. BGI Genomics
  26. biocrates life sciences
  27. Biomedical Research Core Facilities, University of Michigan
  28. Biosfer Teslab
  29. Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles 
  30. BioXenClue
  31. BioZone 
  32. Boehringer Ingelheim
  33. Boston University
  34. BPS Bioscience
  35. Brigham and Women’s Hospital
  36. Bristol Myers Squibb
  37. CD BioSciences
  38. CECAD, University of Cologne
  39. Cedars-Sinai
  40. Center for Iron and Hematology Disorders, University of Utah
  41. Centre for Cellular and Molecular Platforms (C-CAMP)
  42. Centre for Omic Sciences (COS)
  43. Centre for Organismal Studies, Heidelberg University
  44. Chalmers University of Technology
  45. Champions Oncology
  46. Chenomx
  47. Children's Hospital of Philadelphia
  48. CHUM Research Center
  49. CIC bioGUNE Basque Research and Technology Alliance
  50. Cincinnati Children's Hospital Medical Center
  51. Clarus Analytical
  52. Cleveland Clinic Lerner Research Institute
  53. Cornell Institute of Biotechnology (CIB)
  54. Creative Bioarray
  55. Creative Biogene
  56. Creative Proteomics 
  57. Cytomics
  58. Dana Faber Cancer Insitute
  59. Department of Chemistry, University of Oxford
  60. Diabetes Research Center, Washington University School of Medicine in St. Louis
  61. DNA Genotek
  62. DNA Xperts
  63. Duke Center for Genomic and Computational Biology (GCB)
  64. Duke-NUS Medical School
  65. Eremid Research Services
  66. European Molecular Biology Laboratory (EMBL)
  67. Evotec
  68. Faculty of Biology, Ludwig-Maximilians-Universität München
  69. Firalis
  70. Fraunhofer ITEM
  71. Fred Hutchinson Cancer Research Center 
  72. Frontage Laboratories
  73. Functional Genomics Center Zurich (FGCZ)
  74. Fundación MEDINA
  75. Gemini Biosciences
  76. General Metabolics
  77. Georgetown Lombardi Comprehensive Cancer Center
  78. Germans Trias i Pujol Research Institute (IGTP)
  79. Gillings School of Global Public Health
  80. Giotto Biotech
  81. GlaxoSmithKline
  82. Helmholtz Zentrum München
  83. HRL Holdings
  84. HTG Molecular Diagnostics
  85. Human Longevity
  86. Human Metabolome Technologies (HMT)
  87. Humboldt Universität zu Berlin
  88. Immuron 
  89. Impulse Dynamics
  90. Indiana Clinical and Translational Sciences Institute (CTSI)
  91. Inivata
  92. Institut Pasteur
  93. Ion Source & Biotechnologies (ISB) 
  94. IRBM
  95. Irving Institute for Clinical and Translational Research
  96. ITSI-BIOSCIENCES
  97. James Hutton Institute
  98.  John Innes Centre
  99.  JUNO Metabolomics
  100. J-VPD
  101. Karolinska Institutet
  102. Leiden University Medical Center
  103. Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKUMed)
  104. Lifeasible
  105. Liquidia Corporation
  106. M. J. Murdock Metabolomics Laboratory, Washington State University
  107. Maastricht UMC+ 
  108. MachPhy Solutions
  109. Max Delbrück Center for Molecular Medicine
  110. Max Planck Institute for Biology of Ageing
  111. Max Planck Institute for Molecular Genetics (MPI-MG)
  112. Max Planck Institute for Terrestrial Microbiology
  113. Max Planck Institute of Immunobiology and Epigenetics
  114. Mayo Clinic
  115. MD Anderson Cancer Center
  116. Medicilon
  117. Merck
  118. MetaboHUB
  119. Metabolite Profiling Core Facility, Whitehead Institute
  120. Metabolomics Core, North Carolina Diabetes Research Center
  121. Metabolon
  122. Metabolytica
  123. Metabo-Profile 
  124. Metanomics Health 
  125. metaSysX 
  126. Metdia Biotech
  127. Monash University
  128. Montreal Heart Institute
  129. MRC Cancer Unit, University of Cambridge
  130. MS-Omics
  131. MtoZ Biolabs
  132. MTT Lab
  133. Muses Labs
  134. MYOS Corporation
  135. National Biomedical Resource Indigenisation Consortium (NBRIC)
  136. National Insitute of Allergy and Infectious Diseases
  137. National Institute on Aging
  138. Nebraska Center for Biotechnology, University of Nebraska-Lincoln
  139. Next Trillion Sciences
  140. North Carolina Biotechnology Center (NCBiotech)
  141. North Carolina Research Campus (NCRC)
  142. North Carolina State University
  143. Northwest Metabolomics Research Cente (NW-MRC)
  144. North-West University (NWU)
  145. Northwestern University
  146. Novelgene Technologies
  147. Novo Nordisk
  148. numares
  149. NuSirt Biopharma
  150. NYU Langone Health
  151. OmicsGen LifeSciences
  152. Oncology Institute of Southern Catalonia
  153. Osaka University
  154. Ospedale San Raffaele
  155. OWL 
  156. Pacific Biosciences
  157. Parker H
  158. Perlman School of Medicine, University of Pennsylvania
  159. Pharmacogenomics Laboratory, Université Laval
  160. Pharmalegacy Laboratories
  161. Pharmaron
  162. PhenoSwitch Bioscience
  163. Philippine Genome Center (PGC)
  164. Philips
  165. Phylogene 
  166. PROMETHEUS METABOLOMICS 
  167. ProSciento
  168. Proteome Factory
  169. Quintara Discovery (QDI)
  170. Redox Biology Centre (RBC), University of Nebraska-Lincoln
  171. Rosalind and Morris Goodman Cancer Institute, McGill University
  172. Roy J
  173. RTI International 
  174. Rubio Laboratorios
  175. Ruiyi Biotechnology
  176. Rutgers Cancer Institute
  177. Sagimet Biosciences
  178. Sandor Speciality Diagnostics 
  179. Sanyal Biotechnology
  180. Sartorius 
  181. SCIEX
  182. Segal Cancer Proteomics Centre (SCPC) 
  183. SGS 
  184. Swedish Metabolomics Centre (SMC), SciLifeLab
  185. Synbio Technologies
  186. SYNLAB Group
  187. System Biosciences (SBI)
  188. Systems Biology Lab
  189. Takeda
  190. Technion-Israel Institute of Technology
  191. Texas A&M University
  192. TGA Sciences
  193. The Arctic University of Norway (UiT)
  194. The Australian Wine Research Institute (AWRI)
  195. The Canadian Frailty Network
  196. The Canadian Longitudinal Study of Aging
  197. The Center for Innovative Technology (CIT), Vanderbilt University
  198. The McMaster Institute for Research on Aging
  199. The Metabolomics Innovation Centre (TMIC)
  200. The Ohio State University
  201. The University of Edinburgh
  202. The University of Melbourne
  203. The University of Tennessee Health Science Center
  204. The University of Western Australia
  205. The Wistar Institute
  206. Thermo Fischer Scientific
  207. Thomas Jefferson University
  208. Turku Bioscience
  209. U.S. Army Research Institute of Environmental Medicine
  210. U.S. Department of Veterans Affairs
  211. UCLA Metabolomics Centre
  212. University of Alabama at Birmingham
  213. University of Birmingham
  214. University of California, Riverside
  215. University of Cambridge
  216. University of Colorado Anschutz Medical Campus
  217. University of Copenhagen
  218. University of Eastern Piedmont
  219. University of Florida
  220. University of Fribourg
  221. University of Gothenburg
  222. University of Helsinki
  223. University of Lausanne
  224. University of Louisville
  225. University of Maryland School of Pharmacy
  226. University of Minnesota
  227. University of North Texas
  228. University of Oklahoma
  229. University of Oslo
  230. University of Oxford
  231. University of Texas at Dallas
  232. University of Victoria (UVic)
  233. University of Virginia
  234. University of York
  235. UT Southwestern Medical Center
  236. UTMB Mass Spectrometry Facility (MSF) 
  237. Utrecht University
  238. Vanderbilt University
  239. Verso Biosciences
  240. Vienna BioCenter
  241. W. M. Keck Metabolomics Research Laboratory, Iowa State University
  242. Wake Forest School of Medicine
  243. Washington University School of Medicine
  244. Weill Cornell Medicine
  245. Weizmann Institute of Science
  246. West Coast Metabolomics Center
  247. Xell (acquired by Sartorious)
  248. X-omics
  249. Yale University
  250. Yenepoya Research Center (YRC)
  251. Zhejiang Dian Diagnostics

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com